LY75

LY75 Overview

English NameLymphocyte antigen 75Approved Drugs0
Drugs in Clinical Trials2Target SynonymLY75,CD205,Lymphocyte Antigen 75,C-Type Lectin Domain Family 13 Member B,CLEC13B,DEC-205,CD205 Antigen,Gp200-MR6,Ly-75
Highest Development StagePhase 1 Clinical
English NameLymphocyte antigen 75
Target SynonymLY75,CD205,Lymphocyte Antigen 75,C-Type Lectin Domain Family 13 Member B,CLEC13B,DEC-205,CD205 Antigen,Gp200-MR6,Ly-75
Approved Drugs0
Drugs in Clinical Trials2
Highest Development StagePhase 1 Clinical

LY75 Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Mouse (1)Human (1)

  • Tag

    His Tag (2)

  • Conjugate

    Unconjugated (2)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
LY5-H52H3
Human
HEK293
Human LY75 / CD205 Protein, His Tag
LY5-M52H5
Mouse
HEK293
Mouse LY75 / CD205 Protein, His Tag (MALS verified)
Total: 2
  • 1

LY75 Background

lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.

LY75 Synonyms

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Rasdegafusp alfaCDX-1401Phase 2 ClinicalLudwig Institute For Cancer ResearchSarcoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Melanoma; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Uterine Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Skin Melanoma; Uveal melanoma; Oligodendroglioma; Urinary Bladder Neoplasms; Hormone-Resistant Prostate Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Anemia, Refractory; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Colonic Neoplasms; Glioblastoma; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Ovarian Neoplasms
Details
Oberotatug ravtansineOBT-076; MEN1309/OBT076; MEN-1309Phase 1 ClinicalOxford Biotherapeutics Ltd, MenariniSolid tumours; Head and Neck Neoplasms; Carcinoma, Adenoid Cystic; Lymphoma, Non-Hodgkin
Details
  • Overview
  • Product List
  • Clinical Drug Information